We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+5.58%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$279M
AUM Growth
+$2.19M
Cap. Flow
-$7.23M
Cap. Flow %
-2.59%
Top 10 Hldgs %
85.6%
Holding
18
New
1
Increased
11
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.2M
2
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$2.96M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.6M
4
IVC
Invacare Corporation
IVC
+$685K
5
OFIX icon
Orthofix Medical
OFIX
+$216K

Top Sells

Rank Stock Value
1
IPXL
Impax Laboratories, Inc.
IPXL
+$24.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$18.3M
3
UTHR icon
United Therapeutics
UTHR
+$620K
4
AVNS
Avanos Medical
AVNS
+$411K
5
MRK icon
Merck
MRK
+$316K

Sector Composition

Rank Sector Weight
1 Healthcare 79.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$38.9M 13.93%
270,909
-4,855
-2% -$620K
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$366M
$35.4M 12.68%
1,055,719
+55,978
+6% +$1.6M
GILD icon
3
Gilead Sciences
GILD
$162B
$30.1M 10.78%
+420,000
New +$31.2M
SCMP
4
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$25.3M 9.05%
1,863,755
+211,857
+13% +$2.96M
OFIX icon
5
Orthofix Medical
OFIX
$477M
$23.4M 8.37%
645,530
+5,679
+0.9% +$216K
AVNS
6
DELISTED
Avanos Medical
AVNS
$20.9M 7.49%
564,792
-11,493
-2% -$411K
AMGN icon
7
Amgen
AMGN
$208B
$18.6M 6.67%
127,157
+1,119
+0.9% +$168K
MRK icon
8
Merck
MRK
$322B
$14.9M 5.34%
265,012
-5,394
-2% -$316K
CNMD icon
9
CONMED
CNMD
$1.39B
$14.5M 5.21%
328,677
+2,892
+0.9% +$123K
IVC
10
DELISTED
Invacare Corporation
IVC
$14.4M 5.16%
1,102,586
+59,475
+6% +$685K
SRGA
11
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$13.7M 4.91%
140,565
+1,195
+0.9% +$110K
DSCI
12
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$4.63M 1.66%
891,026
+7,026
+0.8% +$33K
VXRT
13
DELISTED
Vaxart
VXRT
$3.37M 1.21%
248,873
+2,190
+0.9% +$33.4K
STRR
14
DELISTED
Star Equity Holdings
STRR
$2.43M 0.87%
9,728
+86
+0.9% +$20.3K
JNP
15
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$1.63M 0.58%
290,853
+2,559
+0.9% +$14K
TEVA icon
16
Teva Pharmaceuticals
TEVA
$40.8B
– –
-397,412
Closed -$18.3M
IPXL
17
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-1,032,187
Closed -$24.5M

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Krensavage Asset Management held 18 positions worth $279M, up 0.79% from $277M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Krensavage Asset Management's Q4 2016 filing shows 1 new, 11 increased, 4 reduced and 2 closed positions. Its largest new stake was Gilead Sciences: 420,000 shares worth $30.1M. The largest sale was Impax Laboratories, Inc., an estimated $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 73% a quarter earlier.

  • Krensavage Asset Management's largest Q4 2016 buy was Gilead Sciences: 420,000 shares worth $30.1M.
  • Krensavage Asset Management added most to Sucampo Pharmaceuticals, Inc. in Q4 2016, an estimated $2.96M increase.
  • Krensavage Asset Management's biggest Q4 2016 reduction was United Therapeutics, cutting an estimated $620K.
  • Krensavage Asset Management fully exited Impax Laboratories, Inc. in Q4 2016, selling an estimated $24.5M.
  • Krensavage Asset Management's ten largest holdings make up 86% of its $279M portfolio in Q4 2016.
  • Krensavage Asset Management opened 1 new position and closed 2 in Q4 2016.
  • Krensavage Asset Management's portfolio value rose 0.79% quarter-over-quarter to $279M.

Based on Krensavage Asset Management's 13F filing for Q4 2016, filed 13 Feb 2017.